Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016

  • ID: 3802747
  • Drug Pipelines
  • 57 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Ablynx NV
  • Amgen Inc.
  • Apogenix GmbH
  • Incyte Corporation
  • MedImmune, LLC
  • Merck & Co., Inc.
  • MORE
Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016

Summary

‘Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Review, H1 2016’, provides in depth analysis on Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted pipeline therapeutics.

The report provides comprehensive information on the Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development and features dormant and discontinued projects.

The author's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from their proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
- The report reviews Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics and enlists all their major and minor projects
- The report assesses Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Ablynx NV
  • Amgen Inc.
  • Apogenix GmbH
  • Incyte Corporation
  • MedImmune, LLC
  • Merck & Co., Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) Overview

Therapeutics Development

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Stage of Development

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Therapy Area

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Indication

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Products under Development by Companies

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Companies Involved in Therapeutics Development

Ablynx NV

Amgen Inc.

Apogenix GmbH

Bristol-Myers Squibb Company

Five Prime Therapeutics, Inc.

Incyte Corporation

MedImmune, LLC

Merck & Co., Inc.

Novartis AG

OncoMed Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Drug Profiles

AMG-228 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986156 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FPA-154 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GWN-323 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCAGN-1876 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LKZ-145 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-1873 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-1248 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MK-4166 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Agonize GITR for Immunology and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize GITR for Hematological Malignacies and Solid Tumors - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Agonize GITR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize GITR for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize GITR for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRX-518 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) - Featured News & Press Releases

Jun 05, 2016: Leap Therapeutics Presents Data from Phase 1 Single Dose Safety Study of Anti-GITR Immunotherapy TRX518 in Patients with Advanced Relapsed or Refractory Solid Tumors at American Society of Clinical Oncology (ASCO) 2016 Annual Meeting

Apr 19, 2016: OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016

Apr 18, 2016: Agenus Presents Poster on Checkpoint Antibody Product Candidate INCAGN01876 at the American Association for Cancer Research (AACR) 2016 Annual Meeting

Jan 21, 2016: Agenus Announces Clearance of Investigational New Drug Application by the FDA for anti-GITR Antibody

Sep 16, 2015: OncoMed Presents Immuno-Oncology Data for GITRL-Fc Candidate at the Inaugural International Cancer Immunotherapy Conference

Apr 05, 2011: Tolerx Presents Preclinical Data On New Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses

Feb 09, 2011: Tolerx Presents Preclinical Data On TRX518

Dec 14, 2010: Tolerx Initiates Phase I Clinical Trial Of TRX518 For Treatment Of Cancer

Dec 01, 2010: Tolerx And Cancer Research Institute Enter Collaboration To Accelerate Development Of TRX518

Jun 25, 2010: Tolerx Reports Preclinical Data On TRX518 For Treatment Of Cancer

Oct 21, 2008: Laureate To Manufacture Tolerx’s TRX518 Antibody

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 57List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Ablynx NV, H1 2016

Pipeline by Amgen Inc., H1 2016

Pipeline by Apogenix GmbH, H1 2016

Pipeline by Bristol-Myers Squibb Company, H1 2016

Pipeline by Five Prime Therapeutics, Inc., H1 2016

Pipeline by Incyte Corporation, H1 2016

Pipeline by MedImmune, LLC, H1 2016

Pipeline by Merck & Co., Inc., H1 2016

Pipeline by Novartis AG, H1 2016

Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016

Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 30List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Ablynx NV
  • Amgen Inc.
  • Apogenix GmbH
  • Incyte Corporation
  • MedImmune, LLC
  • Merck & Co., Inc.
  • MORE
According to the author's, recently published report 'Glucocorticoid Induced Tumor Necrosis Factor Receptor - Pipeline Review, H1 2016'; Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) pipeline Target constitutes close to 15 molecules. Out of which approximately 15 molecules are developed by Companies.

Furthermore, the author says; Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) Glucocorticoid induced tumor necrosis factor receptor or TNFRSF18 or AITR is a protein encoded by TNFRSF18 gene. TNFSF18 is involved in interactions between activated T-lymphocytes and endothelial cells and in the regulation of T-cell receptor-mediated cell death. It mediated NF-kappa-B activation via the TRAF2/NIK pathway.

The report 'Glucocorticoid Induced Tumor Necrosis Factor Receptor - Pipeline Review, H1 2016' outlays comprehensive information on the Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Glucocorticoid Induced Tumor Necrosis Factor Receptor (Activation Inducible TNFR Family Receptor or Glucocorticoid Induced TNFR Related Protein or CD357 or TNFRSF18) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 5, 1, 7 and 1 respectively.
Note: Product cover images may vary from those shown
5 of 5
Ablynx NV
Amgen Inc.
Apogenix GmbH
Bristol-Myers Squibb Company
Five Prime Therapeutics, Inc.
Incyte Corporation
MedImmune, LLC
Merck & Co., Inc.
Novartis AG
OncoMed Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll